Toxicology hiring is small-pool, high-stakes, and disproportionately determines IND timing. Recruits Lab runs tox searches from a maintained map of every U.S. tox scientist and director with active IND-enabling ownership — because there is no other way to source this specialty at speed.
Toxicology is one of the highest-stakes hiring areas in drug development. A weak IND-enabling toxicology hire shows up as IND clinical holds, additional studies, and lost runway. A weak late-stage tox leader misses signals that surface in the clinic or, worse, in post-marketing safety.
Recruits Lab places toxicology talent across IND-enabling, late-stage, and post-marketing safety functions. Our practice spans general toxicology, reproductive toxicology, juvenile toxicology, genetic toxicology, safety pharmacology, and DMPK-adjacent toxicology roles.
Our recruiters understand the distinctions that matter — study director with real GLP study ownership versus contributors, regulatory toxicologist with direct FDA interaction versus those who have only authored sections, and IND-enabling versus late-stage NDA/BLA campaigns. We screen for the experience that maps to your program.
Many strong toxicology candidates sit at CROs and large pharma. We screen for the sponsor-side cultural shift and the ability to work the pace and ambiguity of a venture-backed program. Counter-offers from current employers are common and we manage them directly.
Subscription pricing is the right fit for programs that need to staff a full IND-enabling tox campaign across multiple roles. A single contingency invoice often costs more than a quarter of subscription with unlimited active roles.
Why this market is hard to recruit for. And how we solve each one.
Strong CRO toxicologists can transition to sponsor work, but the move requires cultural calibration. We screen for it.
Many candidates have run GLP studies; fewer have actually owned them as study directors. We screen for true ownership.
IND, IMPD, and CTA authoring is rarer than resumes suggest. We assess for direct authoring versus contribution.
Biologics, ADCs, and cell or gene therapy each have modality-specific safety considerations. We screen for direct modality experience.
Big pharma toxicologists often struggle with venture-backed velocity. We screen for the cultural shift.
Toxicology talent is in chronic short supply. Counter-offers are aggressive and we manage them directly.
The repeatable system behind our 14-day average hire time.
We run a deep intake call with hiring managers and scientific leadership covering technical must-haves, dealbreakers, comp band, equity philosophy, and the cultural traits that predict success in your specific stage and program.
We build a fresh map of 80-150 qualified candidates from direct competitors, academic spinouts, CROs, and adjacent therapeutic areas. No database scraping — real research from a recruiter who understands the science.
Personalized outreach from a senior recruiter who can actually discuss your molecule, mechanism, or modality. Response rates run 3-5x higher than generalist agencies because the first message reads like it came from another scientist.
Five to eight vetted candidates with structured profile briefs covering technical fit, motivation, publication record where relevant, comp expectations, and risk factors. Not a resume dump — a decision document.
We manage offer construction, counter-offer scenarios, resign coaching, and start-date negotiation. Every placement carries a 90-day replacement guarantee at no additional fee.
Original observations from live searches in this specialty.
Many candidates list IND-enabling toxicology as experience because their group contributed to a package. Real ownership means designing the tox strategy, running the studies, and writing the IND-tox sections that FDA read. We verify by asking which specific studies the candidate designed and defended in FDA response cycles.
Small-molecule tox does not translate cleanly to biologics tox, and neither translates to cell/gene therapy tox. In 2026 the pool of directors with cell/gene-specific IND-enabling tox is under 150 people nationally. We know most of them by name.
For a pre-clinical biotech, a tox leader who has managed studies at multiple CROs and knows which CROs are strong on which modality is often more valuable than an in-house tox scientist. We flag this profile explicitly for stage-appropriate hiring managers.
2026 U.S. base salary ranges for toxicology roles at venture-backed and mid-cap life sciences companies. Excludes equity, bonus, and sign-on. Ranges reflect Series A through commercial-stage benchmarks.
| Role | Base Salary Range |
|---|---|
| Toxicologist II | $140K–$180K |
| Senior Toxicologist | $165K–$215K |
| Principal Toxicologist | $200K–$255K |
| Study Director, GLP Tox | $185K–$240K |
| Director, Nonclinical Safety | $240K–$310K |
| Senior Director, Tox | $280K–$360K |
| VP, Nonclinical Development | $330K–$430K |
Source: Recruits Lab 2026 Life Sciences Compensation dataset.
Quick answers to the questions founders and hiring leaders ask most.
Toxicology recruiters source, screen, and qualify nonclinical safety scientists, study directors, and leadership for biotech and pharma programs. Recruits Lab specializes in toxicology and averages 14 days from kickoff to offer.
Industry average for senior and principal toxicology roles is 90 to 150 days. Recruits Lab averages 14 days.
Yes. Study directors with direct GLP ownership are a frequent search profile, including both CRO and sponsor placements.
Yes. Multi-role IND-enabling tox builds are routine engagements on subscription.
Subscription starts at $7,500 per month with unlimited active roles. Contingency is a flat 20 percent with a 90-day guarantee.
Director of Nonclinical Safety with ADC tox experience needed before IND filing. Internal recruiting had filled zero candidates in five months.
Mapped 41 ADC-experienced toxicology leaders across competitor programs and large pharma. Senior recruiter ran outbound and presented a four-person shortlist in 13 days.
Offer accepted in 22 days. IND filed on the original timeline.
"Recruits Lab understood the science from day one. They sent four interview-ready candidates inside two weeks after our internal team had spent three months on the role."
"Their subscription model let us close three scientific hires in a single quarter for less than what a single retained search would have cost us."
Yes. Specialty tox including DART and juvenile programs are part of the practice.
Yes. Safety pharm is a frequent adjacent search to general toxicology.
Yes. GenTox is a routine search profile, particularly for IND-enabling campaigns.
Yes, both directions — sponsor-to-CRO and CRO-to-sponsor — with explicit screening for the operational shift.
Yes. Small molecule, biologics, ADCs, RNA, cell and gene therapy are all part of the practice.
Every placement carries a 90-day replacement guarantee. If a hire leaves or does not work out within the first 90 days, we run the search again at no additional fee.
Yes. We sign NDAs and routinely run confidential and stealth-mode searches for executive replacements, sensitive program leads, and pre-launch hires.
Book a free 30-minute hiring strategy review using the CTA on this page. We will scope the role, suggest a sourcing approach, and quote a subscription or contingency option that fits your stage.
Compensation data, hiring playbooks, case studies, and related recruiting specialties.
Four ways to engage. Pick whichever matches where you are.
30-minute strategy review with a senior recruiter. Free, no commitment.
Get startedTell us about the role. We respond with a calibration call within 24 hours.
Get startedSend a job description. We confirm fit and quote a subscription or contingency engagement.
Get startedSenior candidates: get represented to our active hiring pipeline.
Get startedRelated Resources
Hand-picked salary guides, market reports, and recruiter pages related to this topic. Authored by Darren Nelson and the Recruits Lab team.
Schedule a free 30-minute Hiring Strategy Review and walk away with a clear plan tailored to your roles.